degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatetické novotvary - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
revolade
novartis europharm limited - eltrombopag - purpura, trombocytopenická, idiopatická - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
cernevit prášek pro injekční/infuzní roztok
baxter czech spol. s r.o., praha array - 1256 retinol-palmitÁt; 402 cholekalciferol; 5465 tokoferol-alfa-rrr; 102 kyselina askorbovÁ; 13244 tetrahydrÁt kokaboxylasy; 1261 dihydrÁt sodnÉ soli riboflavin-fosfÁtu; 1230 pyridoxin-hydrochlorid; 425 kyanokobalamin; 644 kyselina listovÁ; 462 dexpanthenol; 173 biotin; 970 nikotinamid - prášek pro injekční/infuzní roztok - vitaminy
nalbuphin orpha 10mg/ml injekční roztok
orpha-devel handels und vertriebs gmbh, purkersdorf array - 9701 nalbufin-hydrochlorid - injekční roztok - 10mg/ml - nalbufin
xenical
cheplapharm arzneimittel gmbh - orlistat - obezita - preparáty proti obezitě, diety - xenical je indikován ve spojení s mírně nízkokalorickou dietou pro léčbu obézní pacienti s indexem tělesné hmotnosti (bmi) vyšší nebo rovnou 30 kg/m2, nebo s nadváhou (bmi video 28 kg/m2) s rizikových faktorů. léčba orlistatem by měla být po 12 týdnech přerušena, pokud se pacientovi nepodařilo zhubnout alespoň 5% tělesné hmotnosti, měřeno na začátku terapie.
levothyroxine aristo 100mcg tableta
aristo pharma gmbh, berlin array - 828 sodnÁ sŮl levothyroxinu - tableta - 100mcg - sodnÁ sŮl levothyroxinu
levothyroxine aristo 125mcg tableta
aristo pharma gmbh, berlin array - 828 sodnÁ sŮl levothyroxinu - tableta - 125mcg - sodnÁ sŮl levothyroxinu
levothyroxine aristo 150mcg tableta
aristo pharma gmbh, berlin array - 828 sodnÁ sŮl levothyroxinu - tableta - 150mcg - sodnÁ sŮl levothyroxinu
levothyroxine aristo 200mcg tableta
aristo pharma gmbh, berlin array - 828 sodnÁ sŮl levothyroxinu - tableta - 200mcg - sodnÁ sŮl levothyroxinu
levothyroxine aristo 25mcg tableta
aristo pharma gmbh, berlin array - 828 sodnÁ sŮl levothyroxinu - tableta - 25mcg - sodnÁ sŮl levothyroxinu